TRIM13 in situ engineering boosts anti-inflammatory capacity of CAR-Ms for liver fibrosis therapy - PubMed
3 hours ago
- #CAR-Ms
- #Liver Fibrosis
- #TRIM13
- TRIM13 engineering enhances the anti-inflammatory capacity of CAR-Ms for liver fibrosis therapy.
- Efferocytosis-sparked lipid nanoparticles (ESLNPs) co-deliver TRIM13 and anti-FAP CAR mRNA to reprogram macrophages.
- Reprogrammed CAR-Ms sustain an anti-inflammatory phenotype by blocking the mtDNA-STING pathway via TRIM13 overexpression.
- ESLNP treatment in mice with liver fibrosis significantly reduces fibrosis and restores hepatic function.
- Sustaining the anti-inflammatory phenotype of CAR-Ms improves their therapeutic efficacy in liver fibrosis.